![Joachim Koch: We evolved and implemented a novel HPLC method to guide selection of antibody drug candidates.](https://oncodaily.com/pub/uploads/2023/08/Joachim-Koch-2-e1692915199270-1280x1163.jpeg)
Photo from Joachim Koch/LinkedIn
Aug 24, 2023, 18:13
Joachim Koch: We evolved and implemented a novel HPLC method to guide selection of antibody drug candidates.
Quoting Joachim Koch, the Vice President of Discovery Research & Translational Immunology at Affimed, on LinkedIn:
”Our latest paper is out in mAbs:
The paper describes how we evolved and implemented a novel HPLC method to guide selection of antibody drug candidates. In particular, this method allows for more physiological estimation of the serum half-life of drug candidates derived from our ROCK® platform reducing the need for cumbersome and costly mouse PK studies.”
For the article click here.
Source: Joachim Koch/LinkedIn
Jul 27, 2024, 19:56